Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value

This article was originally published in The Pink Sheet Daily

Executive Summary

The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.

Advertisement

Related Content

ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
Bristol Offloads HIV Pipeline To ViiV As It Tightens Focus
HIV Drug Sales Rescue GSK's Second Quarter
Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth
Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth
Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth
Swapping Assets Now Down To Execution For GSK And Novartis
GSK Sets Sights On ViiV HIV Spin-Out In 2016
Tivicay Launch Returns ViiV To HIV Spotlight And Growth
Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel